Axel Matzdorff

2.8k total citations
76 papers, 1.3k citations indexed

About

Axel Matzdorff is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Axel Matzdorff has authored 76 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Hematology, 15 papers in Genetics and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Axel Matzdorff's work include Platelet Disorders and Treatments (39 papers), Blood groups and transfusion (21 papers) and Venous Thromboembolism Diagnosis and Management (15 papers). Axel Matzdorff is often cited by papers focused on Platelet Disorders and Treatments (39 papers), Blood groups and transfusion (21 papers) and Venous Thromboembolism Diagnosis and Management (15 papers). Axel Matzdorff collaborates with scholars based in Germany, United States and Austria. Axel Matzdorff's co-authors include B. Kemkes‐Matthes, H. Pralle, Anthony Maraveyas, Ingrid Pabinger, Simon Noble, Helmut Ostermann, V. Kiefel, Jürg H. Beer, K. Matthes and Oliver Meyer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Axel Matzdorff

70 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Axel Matzdorff Germany 20 747 249 247 243 230 76 1.3k
Marietta Kollars Austria 17 690 0.9× 165 0.7× 493 2.0× 340 1.4× 137 0.6× 31 1.3k
Kristen M. Sanfilippo United States 19 395 0.5× 186 0.7× 477 1.9× 288 1.2× 311 1.4× 101 1.2k
Rudolf Pihusch Germany 21 685 0.9× 141 0.6× 154 0.6× 111 0.5× 211 0.9× 43 1.2k
Laura Russo Italy 22 575 0.8× 464 1.9× 652 2.6× 350 1.4× 261 1.1× 56 1.7k
Ho‐Young Yhim South Korea 17 286 0.4× 203 0.8× 244 1.0× 156 0.6× 361 1.6× 116 1.2k
Silvia Koder Austria 19 636 0.9× 110 0.4× 683 2.8× 358 1.5× 207 0.9× 36 1.3k
K. J. Roozendaal Netherlands 20 507 0.7× 187 0.8× 171 0.7× 294 1.2× 381 1.7× 40 1.9k
Darko Antić Serbia 14 297 0.4× 203 0.8× 273 1.1× 151 0.6× 170 0.7× 96 823
Sergio Siragusa Italy 26 960 1.3× 470 1.9× 748 3.0× 595 2.4× 242 1.1× 150 2.1k
Sergio Storti Italy 20 740 1.0× 545 2.2× 262 1.1× 119 0.5× 419 1.8× 72 1.7k

Countries citing papers authored by Axel Matzdorff

Since Specialization
Citations

This map shows the geographic impact of Axel Matzdorff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Matzdorff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Matzdorff more than expected).

Fields of papers citing papers by Axel Matzdorff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Matzdorff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Matzdorff. The network helps show where Axel Matzdorff may publish in the future.

Co-authorship network of co-authors of Axel Matzdorff

This figure shows the co-authorship network connecting the top 25 collaborators of Axel Matzdorff. A scholar is included among the top collaborators of Axel Matzdorff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Matzdorff. Axel Matzdorff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matzdorff, Axel, Sonja Alesci, Johanna Gebhart, et al.. (2023). Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland. Oncology Research and Treatment. 46(Suppl. 2). 5–44. 13 indexed citations
2.
Middeke, Jan Moritz, et al.. (2023). Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP. Blood Advances. 7(14). 3710–3724. 14 indexed citations
3.
Matzdorff, Axel, Sonja Alesci, Johanna Gebhart, et al.. (2022). Expertenreport Immunthrombozytopenie – Aktuelle Diagnostik und Therapie. Oncology Research and Treatment. 46(Suppl. 1). 7–56.
4.
Matzdorff, Axel, Oliver Meyer, Helmut Ostermann, et al.. (2018). Immunthrombozytopenie - aktuelle Diagnostik und Therapie: Empfehlungen einer gemeinsamen Arbeitsgruppe der DGHO, ÖGHO, SGH, GPOH und DGTI. Oncology Research and Treatment. 41(Suppl. 2). 5–36. 5 indexed citations
5.
Matzdorff, Axel, Oliver Meyer, Helmut Ostermann, et al.. (2018). Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncology Research and Treatment. 41(Suppl. 5). 1–30. 78 indexed citations
6.
7.
Noble, Simon, et al.. (2015). Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica. 100(11). 1486–1492. 85 indexed citations
8.
Boige, Valérie, Marc Vincent, Jan Stoehlmacher, et al.. (2015). DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.. Journal of Clinical Oncology. 33(15_suppl). 3584–3584. 1 indexed citations
9.
10.
Brown, T. Michelle, Ruslan Horblyuk, Kelly M. Grotzinger, Axel Matzdorff, & Chris L. Pashos. (2012). Patient-reported treatment burden of chronic immune thrombocytopenia therapies. PubMed. 12(1). 2–2. 30 indexed citations
11.
Matzdorff, Axel, et al.. (2011). Advances in ITP – Therapy and Quality of Life – A Patient Survey. PLoS ONE. 6(11). e27350–e27350. 14 indexed citations
12.
Matzdorff, Axel, Aristoteles Giagounidis, Andreas Greinacher, et al.. (2010). Diagnostik und Therapie der Immunthrombozytopenie. Onkologie. 33(3). 2–20. 24 indexed citations
13.
Hofheinz, Ralf‐Dieter, Frederik Wenz, Stefan Post, et al.. (2009). Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Safety results of a randomized, phase III trial. Journal of Clinical Oncology. 27(15_suppl). 4014–4014. 43 indexed citations
14.
Gauler, Thomas, Axel Matzdorff, Allan B. Dietz, et al.. (2008). Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer. Journal of Clinical Oncology. 26(15_suppl). 6066–6066. 5 indexed citations
15.
16.
Matzdorff, Axel, et al.. (2005). Upregulation of GP IIb/IIIa receptors during platelet activation: Influence on efficacy of receptor blockade. Thrombosis Research. 117(3). 307–314. 5 indexed citations
17.
Sachs, Ulrich J., et al.. (2003). Bernard–Soulier syndrome due to the homozygous Asn‐45Ser mutation in GPIX: an unexpected, frequent finding in Germany. British Journal of Haematology. 123(1). 127–131. 26 indexed citations
18.
Kemkes‐Matthes, B., et al.. (2002). Markers of platelet activation and platelet–leukocyte interaction in patients with myeloproliferative syndromes. Thrombosis Research. 108(2-3). 139–145. 93 indexed citations
19.
Matzdorff, Axel, et al.. (2001). Perioperative management of a patient with Fechtner syndrome. Annals of Hematology. 80(7). 436–439. 11 indexed citations
20.
Matzdorff, Axel, et al.. (2000). Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro. Journal of Laboratory and Clinical Medicine. 135(3). 247–255. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marietta Kollars Breakdown of academic impact, for papers by Kristen M. Sanfilippo Breakdown of academic impact, for papers by Rudolf Pihusch Breakdown of academic impact, for papers by Laura Russo Breakdown of academic impact, for papers by Ho‐Young Yhim Breakdown of academic impact, for papers by Silvia Koder Breakdown of academic impact, for papers by K. J. Roozendaal Breakdown of academic impact, for papers by Darko Antić Breakdown of academic impact, for papers by Sergio Siragusa Breakdown of academic impact, for papers by Sergio Storti
Rankless by CCL
2026